Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure o… Read more
Lexicon Pharmaceuticals Inc (LXRX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.160x
Based on the latest financial reports, Lexicon Pharmaceuticals Inc (LXRX) has a cash flow conversion efficiency ratio of -0.160x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.23 Million) by net assets ($107.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Lexicon Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Lexicon Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Lexicon Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lexicon Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Palfinger AG
PINK:PLFRF
|
0.205x |
|
Sats ASA
OL:SATS
|
0.451x |
|
TUHU Car Inc.
F:L83
|
N/A |
|
Guangdong Huate Gas Co Ltd
SHG:688268
|
0.046x |
|
Akfen Yenilenebilir Enerji A.S.
IS:AKFYE
|
0.050x |
|
Dalian Dalicap Technology Co Ltd
SHE:301566
|
N/A |
|
Beijing Jingcheng Machinery Electric Co Ltd
SHG:600860
|
0.058x |
|
Aoshikang Technology Co Ltd Class A
SHE:002913
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Lexicon Pharmaceuticals Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Lexicon Pharmaceuticals Inc from 1999 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $107.54 Million | $-67.85 Million | -0.631x | +48.49% |
| 2024-12-31 | $145.95 Million | $-178.78 Million | -1.225x | +29.55% |
| 2023-12-31 | $93.11 Million | $-161.90 Million | -1.739x | -129.21% |
| 2022-12-31 | $117.12 Million | $-88.85 Million | -0.759x | +0.97% |
| 2021-12-31 | $113.59 Million | $-87.02 Million | -0.766x | +16.22% |
| 2020-12-31 | $156.37 Million | $-142.97 Million | -0.914x | -194.08% |
| 2019-12-31 | $117.10 Million | $113.81 Million | 0.972x | -82.73% |
| 2018-12-31 | $-26.41 Million | $-148.61 Million | 5.628x | +258.17% |
| 2017-12-31 | $52.10 Million | $-185.39 Million | -3.558x | -218.90% |
| 2016-12-31 | $157.40 Million | $-175.63 Million | -1.116x | -272.62% |
| 2015-12-31 | $285.85 Million | $184.78 Million | 0.646x | +342.78% |
| 2014-12-31 | $284.02 Million | $-75.62 Million | -0.266x | +50.26% |
| 2013-12-31 | $170.16 Million | $-91.08 Million | -0.535x | -51.11% |
| 2012-12-31 | $266.68 Million | $-94.46 Million | -0.354x | -19.86% |
| 2011-12-31 | $297.57 Million | $-87.94 Million | -0.296x | +11.37% |
| 2010-12-31 | $247.02 Million | $-82.37 Million | -0.333x | +38.76% |
| 2009-12-31 | $163.50 Million | $-89.02 Million | -0.544x | -11.53% |
| 2008-12-31 | $195.83 Million | $-95.60 Million | -0.488x | -88.23% |
| 2007-12-31 | $286.57 Million | $-74.32 Million | -0.259x | +61.03% |
| 2006-12-31 | $85.50 Million | $-56.91 Million | -0.666x | -343.62% |
| 2005-12-31 | $85.80 Million | $23.44 Million | 0.273x | +178.62% |
| 2004-12-31 | $121.59 Million | $-42.26 Million | -0.348x | -648.61% |
| 2003-12-31 | $166.22 Million | $-7.72 Million | -0.046x | +72.61% |
| 2002-12-31 | $169.90 Million | $-28.79 Million | -0.169x | -105.70% |
| 2001-12-31 | $218.37 Million | $-17.99 Million | -0.082x | -1039.20% |
| 2000-12-31 | $207.63 Million | $-1.50 Million | -0.007x | +99.38% |
| 1999-12-31 | $8.20 Million | $-9.60 Million | -1.171x | -- |